Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyCigna Opzelura Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0369

    Opzelura (ruxolitinib 1.5% cream) Coverage Policy

    Customize your policy alerts

    Sign up for Cigna Policy IP0369 alerts

    Get alerted when Policy IP0369 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Opzelura cream for atopic dermatitis and nonsegmental vitiligo. It applies to providers requesting coverage under Cigna-administered health benefit plans.

    Policy Summary
    PayerCigna
    PolicyOpzelura (ruxolitinib 1.5% cream) Coverage Policy
    Policy CodePolicy IP0369
    Change TypeModified
    Effective DateNov 15, 20261d
    Last ReviewOct 22, 2026
    Next Review DateNot scheduled
    Key ActionObtain prior authorization for Opzelura cream and document that the applicable indication criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    An exception was added to the prescription topical corticosteroid trial requirement when treating atopic dermatitis or vitiligo involving the face, eyes or eyelids, skin folds, axillae, or genitalia.

    The anatomic-site criterion for atopic dermatitis and vitiligo was expanded to include axillae and examples of skin folds.

    Zeposia and Velsipity were removed from the appendix examples of other therapeutic biologics and JAK inhibitors.

    Generic products for Xeljanz and Xeljanz XR were added to the appendix examples of other JAK inhibitors.

    Exdensur and Anzupgo were added to the appendix examples of therapies relevant to prohibited concurrent use.

    2FDA-approved covered indications
    ≥2 yearsMinimum age for atopic dermatitis coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥12 yearsMinimum age for vitiligo coverage
    20% BSAMaximum atopic dermatitis involvement for coverage
    10% BSAMaximum vitiligo involvement for coverage
    8 weeks / 6 monthsInitial approval duration

    Medical Necessity and Covered Indications

    Atopic Dermatitis

    Covered when ONE indication pathway is met. For atopic dermatitis, approve for 8 weeks when all criteria below are satisfied.

    Core criteria: Patient is at least 2 years old; according to the prescriber, has mild to moderate atopic dermatitis; and atopic dermatitis involvement affects no more than 20% of body surface area.Age ≥2 years; BSA ≤20%

    Topical treatment pathway

    • Corticosteroid pathway

      • Failed corticosteroid trial: Tried at least one medium-, medium-high-, high-, and/or super-high-potency prescription topical corticosteroid; applied it daily for at least 28 consecutive days; and, according to the prescriber, demonstrated inadequate efficacy.≥28 consecutive days

        Concomitant use of a topical corticosteroid with a topical calcineurin inhibitor meets this requirement.

      • Sensitive-site exception: Atopic dermatitis affects the face, eyes or eyelids, skin folds (e.g., abdomen, neck, or under the breasts), axillae, and/or genitalia.
    • Topical calcineurin inhibitor requirement: Tried at least one topical calcineurin inhibitor; applied it daily for at least 28 consecutive days; and, according to the prescriber, demonstrated inadequate efficacy.≥28 consecutive days

      Examples include tacrolimus ointment or pimecrolimus cream. Concomitant use with a topical corticosteroid meets this requirement.

    Specialist prescribing: Medication is prescribed by, or in consultation with, an allergist, immunologist, or dermatologist.

    Vitiligo

    Covered when all criteria in the vitiligo pathway are met. Approve for 6 months when the criteria below are satisfied.

    Core criteria: Patient is at least 12 years old; has nonsegmental vitiligo; and vitiligo involvement affects no more than 10% of body surface area.Age ≥12 years; BSA ≤10%

    Topical treatment pathway

    • Corticosteroid pathway

      • Failed corticosteroid trial: Tried at least one high- and/or super-high-potency prescription topical corticosteroid; used it for at least 12 weeks, intermittently or continuously; and, according to the prescriber, demonstrated inadequate efficacy.≥12 weeks

        Concomitant use of a topical corticosteroid with a topical calcineurin inhibitor meets this requirement.

    Concurrent use of Opzelura with therapeutic biologics or other JAK inhibitors is not recommended and is considered not medically necessary. These therapies were prohibited during pivotal studies, and safety and efficacy data for combination use are unavailable.

    Concurrent use of Opzelura with potent immunosuppressants, including azathioprine or cyclosporine, is not recommended and is considered not medically necessary. Systemic immunosuppressants were prohibited during pivotal studies, and safety and efficacy data for combination use are unavailable.

    Use of Opzelura for alopecia is not medically necessary. Opzelura is not indicated for alopecia, and a Phase II study in alopecia areata did not demonstrate significant improvement in hair regrowth compared with vehicle.

    Use of Opzelura for plaque psoriasis is not medically necessary. Opzelura is not indicated for plaque psoriasis, and available Phase II clinical data are very limited.

    Concurrent use of Opzelura with a therapeutic biologic or another JAK inhibitor is considered not medically necessary because these combinations were prohibited in pivotal studies and their safety and efficacy have not been established.

    Concurrent use of Opzelura with another potent immunosuppressant, including azathioprine or cyclosporine, is considered not medically necessary because systemic immunosuppressants were prohibited in pivotal studies and combination safety and efficacy data are unavailable.

    Use of Opzelura for alopecia is considered not medically necessary because it is not an indicated use and available Phase II data did not demonstrate significant improvement in hair regrowth.

    Use of Opzelura for plaque psoriasis is considered not medically necessary because it is not an indicated use and available clinical data are very limited.

    Use of Opzelura for any indication other than the policy's FDA-approved atopic dermatitis or nonsegmental vitiligo pathways is considered not medically necessary.

    Any use of Opzelura outside the covered indications is considered not medically necessary, including concurrent use with therapeutic biologics or other JAK inhibitors, concurrent use with potent immunosuppressants such as azathioprine or cyclosporine, and treatment of alopecia or plaque psoriasis.

    Clinical Thresholds and Prior Therapy Parameters

    Atopic Dermatitis Affected Body Surface Area
    Coverage limitAtopic dermatitis involvement must affect no more than 20% of body surface area (BSA).
    Covered conditionMild to moderate atopic dermatitis.
    ApplicationOpzelura is applied twice daily to affected areas.
    Vitiligo Affected Body Surface Area
    Coverage limitVitiligo involvement must affect no more than 10% of BSA.
    Covered conditionNonsegmental vitiligo.
    Application

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Opzelura cream.

    Prior Authorization

    Indication-Specific Approval Duration

    Approvals are indication-specific and are limited to the duration stated in the policy.

    • Atopic dermatitis: 8 weeks.
    • Vitiligo: 6 months (1 month equals 30 days).
    Step Therapy

    Required Topical Therapy Trials

    Document the required prior topical therapy trials and inadequate efficacy for the treated indication. Coverage criteria differ for atopic dermatitis and vitiligo.

    Therapy Overview

    Opzelura (ruxolitinib 1.5% cream) is a topical Janus kinase inhibitor. It is indicated for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients and for topical treatment of nonsegmental vitiligo. Covered treatment is limited to affected areas of up to 20% of body surface area for atopic dermatitis and up to 10% of body surface area for vitiligo.

    Policy Terms and Indication Definitions

    Atopic Dermatitis Indication
    Treatment typeTopical, short-term and non-continuous chronic treatment.
    Disease severityMild to moderate atopic dermatitis.
    Patient populationNonimmunocompromised patients at least 2 years of age whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
    Nonsegmental Vitiligo
    Covered indicationTopical treatment of nonsegmental vitiligo.
    Minimum agePatients must be at least 12 years of age.
    Body surface area limit
    Policy Summary
    PayerCigna
    PolicyOpzelura (ruxolitinib 1.5% cream) Coverage Policy
    Policy CodePolicy IP0369
    Change TypeModified
    Effective DateNov 15, 20261d
    Last ReviewOct 22, 2026
    Next Review DateNot scheduled
    Key ActionObtain prior authorization for Opzelura cream and document that the applicable indication criteria are met.
    SourceLink
    On This Page
    Medical Necessity and Covered IndicationsClinical Thresholds and Prior Therapy ParametersAuthorization, Documentation, and Denial RisksTherapy OverviewPolicy Terms and Indication Definitions
    Sensitive-site exception: Vitiligo affects the face, eyes or eyelids, skin folds (e.g., abdomen, neck, or under the breasts), axillae, and/or genitalia.
  1. Topical calcineurin inhibitor requirement: Tried at least one topical calcineurin inhibitor; applied it daily for at least 12 weeks; and, according to the prescriber, demonstrated inadequate efficacy.≥12 weeks

    Examples include tacrolimus ointment or pimecrolimus cream. Concomitant use with a topical corticosteroid meets this requirement.

    2. Specialist prescribing: Medication is prescribed by, or in consultation with, a dermatologist.
    Opzelura is applied twice daily to affected areas.
    Atopic Dermatitis Minimum Age
    Minimum ageAt least 2 years of age.
    Disease severityMild to moderate atopic dermatitis.
    Patient statusThe patient must be nonimmunocompromised.
    Vitiligo Minimum Age
    Minimum ageAt least 12 years of age.
    Disease subtypeNonsegmental vitiligo.
    Coverage limitVitiligo involvement must affect no more than 10% of BSA.
    Atopic Dermatitis Topical Corticosteroid Duration
    Required durationApplied daily for at least 28 consecutive days.
    Eligible therapyAt least one medium-, medium-high-, high-, and/or super-high-potency prescription topical corticosteroid.
    Response requirementThe prescriber must document inadequate efficacy with the topical corticosteroid therapy.
    Atopic Dermatitis Topical Calcineurin Inhibitor Duration
    Required durationApplied daily for at least 28 consecutive days.
    Required trialThe patient must have tried at least one topical calcineurin inhibitor.
    Response requirementThe prescriber must document inadequate efficacy with the topical calcineurin inhibitor.
    Vitiligo Topical Corticosteroid Duration
    Required durationAt least 12 weeks, with intermittent or continuous use meeting the duration requirement.
    Eligible therapyAt least one high- and/or super-high-potency prescription topical corticosteroid.
    Response requirementThe prescriber must document inadequate efficacy with the topical corticosteroid therapy.
    Vitiligo Topical Calcineurin Inhibitor Duration
    Required durationApplied daily for at least 12 weeks.
    Required trialThe patient must have tried at least one topical calcineurin inhibitor.
    Response requirementThe prescriber must document inadequate efficacy with the topical calcineurin inhibitor.
    • Atopic dermatitis: A qualifying medium-, medium-high-, high-, or super-high-potency prescription topical corticosteroid applied daily for at least 28 consecutive days with inadequate efficacy, unless treating an approved sensitive area; and a topical calcineurin inhibitor applied daily for at least 28 consecutive days with inadequate efficacy.
    • Vitiligo: A qualifying high- or super-high-potency prescription topical corticosteroid used for at least 12 weeks with inadequate efficacy, unless treating an approved sensitive area; and a topical calcineurin inhibitor applied daily for at least 12 weeks with inadequate efficacy.
    • Concomitant use of a topical corticosteroid and topical calcineurin inhibitor satisfies the applicable therapy trial requirement.
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation supporting the indication-specific criteria and prior treatment history.

    • Diagnosis and treated indication.
    • Age and, when applicable, subtype: mild to moderate atopic dermatitis or nonsegmental vitiligo.
    • Disease severity and affected body-surface area: atopic dermatitis ≤20%; vitiligo ≤10%.
    • Prior topical corticosteroid and topical calcineurin inhibitor trials, duration of use, and prescriber-documented inadequate efficacy.
    Documentation Required

    Specialist Involvement Required

    Opzelura must be prescribed by, or used in consultation with, a physician who specializes in the condition being treated.

    • Atopic dermatitis: allergist, immunologist, or dermatologist.
    • Vitiligo: dermatologist.
    Denial Risk

    Authorization or Criteria Not Met

    Requests may be denied when prior authorization is not obtained or when the prescribing, indication, clinical, topical-therapy, specialist, or other policy criteria are not satisfied.

    • Authorization must be obtained before benefit coverage.
    • Claims and requests must support an FDA-approved covered indication and all applicable criteria.
    • Failure to meet documentation or specialist requirements may result in denial.
    Denial Risk

    Prohibited Concomitant Therapy

    Opzelura is not medically necessary when used concurrently with a biologic, another JAK inhibitor, or another potent immunosuppressant because combination safety and efficacy are not established.

    • Do not use with therapeutic biologics or other JAK inhibitors.
    • Do not use with potent immunosuppressants, including azathioprine or cyclosporine.
    Denial Risk

    Non-Covered Diagnoses

    Claims for Opzelura used to treat diagnoses outside the covered FDA-approved indications may be denied as not medically necessary.

    • Alopecia, including alopecia areata, is not a covered medically necessary use.
    • Plaque psoriasis is not a covered medically necessary use.
    • Other uses are not medically necessary under this policy.
    Billing Rule

    Covered Codes Required

    Submit the most appropriate covered diagnosis and procedure codes in effect on the date of submission. Claims without applicable covered codes may be denied as not covered.

    • Verify that the claim includes the applicable covered diagnosis code(s).
    • Use the appropriate procedure code(s) and code set versions for the submission date.
    Denial Risk

    Concurrent Biologic or JAK Inhibitor Use

    Coverage may be denied as not medically necessary when Opzelura is used concurrently with a therapeutic biologic or another JAK inhibitor.

    • Combination use with biologics or other JAK inhibitors is not recommended.
    • Document that the patient is not receiving prohibited concurrent therapy.
    Denial Risk

    Concurrent Potent Immunosuppressant Use

    Coverage may be denied as not medically necessary when Opzelura is used concurrently with a potent immunosuppressant.

    • Examples include azathioprine and cyclosporine.
    • Document that the patient is not receiving a prohibited potent immunosuppressant.
    Denial Risk

    Alopecia Treatment

    Opzelura treatment for alopecia is not medically necessary because it is not an indicated use under this policy.

    • This includes alopecia areata.
    Denial Risk

    Plaque Psoriasis Treatment

    Opzelura treatment for plaque psoriasis is not medically necessary because it is not an indicated use under this policy.

    Vitiligo involvement must affect no more than 10% of BSA.
    Body Surface Area (BSA)
    DefinitionBSA is the estimated percentage of the patient's skin affected by the condition.
    Atopic dermatitis limitAtopic dermatitis treatment is limited to affected areas of up to 20% BSA.
    Vitiligo limitVitiligo treatment is limited to affected areas of up to 10% BSA.